硝苯地平-d6 | 1188266-14-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 硝苯地平-d6
• 中文别名: 硝苯地平-D6
• 英文名称: Nifedipine-d6
• 英文别名: bis(trideuteriomethyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
• CAS: 1188266-14-9
• 化学式: C17H18N2O6
• 分子量: 352.37
• InChiKey: HYIMSNHJOBLJNT-LIJFRPJRSA-N

物化性质

• 熔点：
  164-165°C
• 溶解度：
  氯仿（微溶）、甲醇（微溶、加热）

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  7

制备方法与用途

生物活性方面，Nifedipine D6（代号BAY-a-1040 D6）是Nifedipine的氘代衍生物。作为一种有效的钙离子通道阻滞剂，Nifedipine被广泛应用。

文献信息

• DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES
  申请人：Cardix Therapeutics LLC

  公开号：US20190070184A1

  公开（公告）日：2019-03-07

  Provided herein is a pharmaceutical composition comprising (i) a phosphodiesterase inhibitor or an adenosine receptor antagonist, (ii) a calcium channel blocker, (iii) a histamine H 1 -receptor agonist, a histamine H 2 -receptor agonist, or a histamine H 3 -receptor antagonist, and (iv) a β 2 -adrenoreceptor agonist; wherein at least one of two or more active pharmaceutical compounds is deuterium enriched. Also provided herein is a pharmaceutical composition comprising at least one of two or more deuterated compounds which increase pharmacokinetic half-life (increasing the duration of action) and reduce side effects by allowing for reduction of the dose levels. A method of use thereof pharmaceutical composition for treating, preventing, or ameliorating a cardiovascular disease.
• [EN] DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES<br/>[FR] COMPOSITIONS PHARMACEUTIQUES DEUTÉRÉES ET MÉTHODES DE TRAITEMENT DE MALADIES CARDIOVASCULAIRES
  申请人：CARDIX THERAPEUTICS LLC

  公开号：WO2019194866A1

  公开（公告）日：2019-10-10

  Provided herein is a pharmaceutical composition comprising (i) a phosphodiesterase inhibitor or an adenosine receptor antagonist, (ii) a calcium channel blocker, (iii) a histamine Hi-receptor agonist, a histamine H2-receptor agonist, or a histamine H3-receptor antagonist, and (iv) a β2-adrenoreceptor agonist; wherein at least one of two or more active pharmaceutical compounds is deuterium enriched. Also provided herein is a pharmaceutical composition comprising at least one of two or more deuterated compounds which increase pharmacokinetic half-life (increasing the duration of action) and reduce side effects by allowing for reduction of the dose levels. A method of use thereof pharmaceutical composition for treating, preventing, or ameliorating a cardiovascular disease.